Fast Five Quiz: HER2+ Metastatic Breast Cancer Management

Winston Tan, MD

Disclosures

January 10, 2022

According to the National Comprehensive Cancer Network (NCCN) Breast Cancer Clinical Practice Guidelines, pertuzumab plus trastuzumab plus a taxane is a preferred systemic therapy regimen for recurrent or stage IV HER2+ breast cancer. Pertuzumab plus trastuzumab plus paclitaxel is also listed as a preferred regimen.

For additional information, refer to the 5th European School of Oncology (ESO)–European Society of Medical Oncology (ESMO) International Consensus Guidelines for Advanced Breast Cancer.

Learn more about the treatment of HER2+ breast cancer.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....